DeciBio Consulting Names Carl Schoellhammer Partner, Strengthening Leadership in Advanced Therapies and Strategic Investment

LOS ANGELES--(BUSINESS WIRE)--DeciBio Consulting, LLC, a precision medicine-focused strategic consulting and market intelligence firm, has promoted Carl Schoellhammer, Ph.D., to Partner. Carl leads the firm’s advanced therapies practice and serves as Managing Director of the DeciBio BroadOak BioTools Venture Fund, a joint initiative between DeciBio Ventures and BroadOak Capital Partners.

Carl joined DeciBio with a unique blend of scientific, entrepreneurial, and strategic expertise, bringing with him a passion for innovation in precision medicine. As a consultant, he has advised global biopharma and emerging biotech clients on pipeline strategy, therapeutic prioritization, and bioprocess optimization, with a particular focus on cell and gene therapies. Simultaneously, he has played a key role in developing DeciBio’s investment strategy. As a leader of DeciBio Ventures since its founding in 2021, he has invested in and supported early-stage companies advancing innovation in precision medicine.

“We’re thrilled to welcome Carl Schoellhammer to the DeciBio partnership. Carl has been instrumental in building and scaling our cell and gene therapy practice, bringing deep domain expertise, strategic vision, and a collaborative spirit that embodies the values of our firm,” said Stephane Budel, Co-Founding Partner at DeciBio. “His leadership will be key as we continue to expand our impact in precision medicine and support our clients at the forefront of therapeutic innovation.”

Prior to joining DeciBio, Carl co-founded Suono Bio, a spinout from MIT, with Professor Robert Langer, ScD, and served as the company’s founding CEO. Suono Bio pioneered ultra-rapid drug delivery platforms for inflammatory diseases. Carl holds a Ph.D. in Chemical Engineering from MIT, and earned a B.S. in Chemical Engineering from the University of California, Berkeley.

When asked why he chose to join the partnership, Carl shared, “The thought leadership. We are a nimble, boutique consultancy that really prides itself on our entrepreneurship and the number of initiatives we can do. Joining the partnership now will allow me to have more of a say in some of the firm's direction, and I think we are poised for exciting growth.”

Carl’s promotion to Partner reflects DeciBio’s continued commitment to cultivating visionary leaders who drive meaningful impact across the life sciences. With deep expertise spanning advanced therapies and strategic investment, Carl will play a critical role in advancing DeciBio’s mission to support innovation across the precision medicine ecosystem.

About DeciBio

DeciBio Consulting (www.decibio.com) is a leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating the adoption and impact of technologies enabling precision medicine.

Headquartered in Los Angeles, California, with additional offices in San Francisco, New York City, and London, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.